C12Q 2523/115
Oxidising agents
Official title: oxidising agents
C12Q2523/115 (Oxidising agents) appears on 8 US grants and 9 published applications in this corpus.
Search patents in C12Q- Granted patents
- 8
- Published applications
- 9
- Assignees
- 6
- Inventors
- 12
- Latest grant
- 8 Jul 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2014 | 0 | 1 |
| 2015 | 1 | 0 |
| 2016 | 0 | 1 |
| 2017 | 1 | 1 |
| 2018 | 0 | 0 |
| 2019 | 1 | 1 |
| 2020 | 0 | 2 |
| 2021 | 0 | 1 |
| 2022 | 2 | 0 |
| 2023 | 2 | 1 |
| 2024 | 0 | 0 |
| 2025 | 1 | 0 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods for the epigenetic analysis of DNA, particularly cell-free DNA8 Jul 2025US 12,351,859 B2Clearnote Health, Inc.
- Systems and methods for pre-analytical substrate processing7 Nov 2023US 11,807,900 B2Genomic Health, Inc.
- Methods for the epigenetic analysis of DNA, particularly cell-free DNA25 Apr 2023US 11,634,748 B2Clearnote Health, Inc.
- Methods for the epigenetic analysis of DNA, particularly cell-free DNA15 Mar 2022US 11,274,335 B2Bluestar Genomics, Inc.
- Rapid, low-sample-volume cholesterol and triglyceride assays8 Mar 2022US 11,268,130 B2Labrador Diagnostics LLC
- Methods for the Epigenetic Analysis of DNA, Particularly Cell-Free DNA24 Sep 2026US 2026/0286421 A1Clearnote Health, Inc.
- Methods for the Epigenetic Analysis of DNA, Particularly Cell-Free DNA27 Jul 2023US 2023/0235380 A1Clearnote Health, Inc.
- Methods for the epigenetic analysis of dna, particularly cell-free dna26 Aug 2021US 2021/0262009 A1Bluestar Genomics, Inc.
- Rapid, low-sample-volume cholesterol and triglyceride assays27 Feb 2020US 2020/0063185 A1Theranos IP Company, LLC
- Methods for the epigenetic analysis of dna, particularly cell-free dna23 Jan 2020US 2020/0024643 A1Bluestar Genomics, Inc.
Most cited
By later US patents
- Methods for the epigenetic analysis of DNA, particularly cell-free DNA4US 11,274,335 B2Bluestar Genomics, Inc. · 2022
- Methods for the epigenetic analysis of DNA, particularly cell-free DNA3US 11,634,748 B2Clearnote Health, Inc. · 2023
- Rapid, low-sample-volume cholesterol and triglyceride assays3US 9,051,599 B2Theranos, Inc. · 2015